Redx Pharma’s (REDX) new management team is continuing to focus its financial resources on progressing lead candidates in oncology and fibrotic disease into the clinic. An extensive internal review, led by the new CEO Lisa Anson has reinforced the vision of a streamlined pipeline in these two disease areas, with the aim of progressing drug candidates to deliver clinical proof-of-concept, a key value inflection point. 2019 is expected to be a busy year for REDX, with several major milestones due. The first of these will be the re-start of the Phase I/II trial with RXC004, its porcupine inhibitor, during 1H’19.
If you'd like to be introduced to the team at Redx Pharma, get in touch.Request a meeting